Johnson & Johnson (JNJ)
Two High Conviction Dividend Buys For This Upside-Down Market
FOMO is driving stock market decisions, especially with meme stocks like GameStop and high-flying AI stocks. That's why I prefer discounted dividend stocks over growth stocks, and highlight two picks that offer durable capital returns. Both names carry strong balance sheets, pay well-above market average dividend yields, and are trading at substantial discounts to their historical valuations.
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
J&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
Johnson & Johnson (JNJ) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Johnson & Johnson (JNJ) closed at $145.65, marking a -0.21% move from the previous day.
J&J hit with new class action over talc seeking medical monitoring for cancer
Johnson & Johnson is facing a new proposed class action seeking damages and medical monitoring on behalf of women who have been diagnosed with cancer, or might develop it in the future, allegedly as a result of using the company's baby powder and other talc products.
3 Mega Cap Stock Bargains As Markets Hit All-Time Highs
As markets continue to reach new all-time highs, investors are constantly seeking opportunities that offer both stability and growth potential. With the S&P 500 and Nasdaq recently hitting new all-time highs, investors are out bargain hunting.
Johnson & Johnson (JNJ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Johnson & Johnson (JNJ) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ ) Goldman Sachs 45th Annual Global Healthcare Conference Call June 12, 2024 2:00 PM ET Company Participants Jennifer Taubert - Executive Vice President, Innovative Medicine John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay. Let's get started.
Cancer victims ask court to block J&J talc bankruptcy
A group of cancer victims asked a federal judge to block Johnson & Johnson's proposed bankruptcy settlement of tens of thousands of lawsuits alleging the company's baby powder and other talc products caused their illnesses, according to a court filing.
Johnson & Johnson to pay $700 million settlement over talc products linked to cancer
Johnson & Johnson has agreed to pay $700 million to settle an investigation by 42 U.S. states and Washington, D.C. into its marketing of baby powder and other talc-based products blamed for allegedly causing cancer.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge
Artificial intelligence is forecast to drive an innovation bonanza in healthcare. This innovation boom is expected to increase the human lifespan dramatically.
